Press release from Companies
Publicerat: 2021-06-01 12:01:34
Curasight A/S, CVR no. 35 24 93 89 ("Curasight" or the "Company") held an extraordinary general meeting on 1 June 2021 at 11:00 (CET). Due to the COVID-19 situation, the extraordinary general meeting will be held as a completely electronic meeting without physical attendance.
The agenda for the general meeting was as follows: Election of Dr. Kirsten Drejer as new member of the board of directors Dr. Kirsten Drejer was elected as new member of the board of directors. A list of Dr. Kirsten Drejer’s management positions in other companies is enclosed as appendix 1. Miscellaneous There were no matters to be presented. Appendix 1 Dr. Kirsten Drejer’s current board directorships and management positions 2000 - KD Invest ApS, CEO 2017 - Bioneer A/S (www.bioneer.dk), Chairman of the board 2017 - Antag Therapeutics ApS (www.antag.com), Chairman of the board 2017 - ResoTher Pharma A/S (www.resotherpharma.com), Chairman of the board 2018 - Zealand Pharma A/S (www.zealandpharma.com), Board member For more information regarding Curasight A/S, please contact: Ulrich Krasilnikoff, CEO Phone: +45 22 83 01 60 E-mail: uk@curasight.com Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.
